Physician profile
Eric Van Meter
NPI 1881332914
$3,728.40
in general payments reported to CMS, 2019-2025
25 companies · $1,510 in 2025
The $1,510 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $375 · 2023: $816 · 2024: $1,028 · 2025: $1,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,236 · Education: $99.99 · Entertainment: $17.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,235.87 |
| Education | $99.99 |
| Entertainment | $17.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $461.93 | 2022-2025 | Cequa |
| Mallinckrodt Hospital Products INC. | $420.23 | 2023-2025 | Acthar |
| Alcon Vision LLC | $392.68 | 2023-2025 | Precision 1, Tryptyr, Dailies Total1 |
| Bausch & Lomb Americas INC. | $372.45 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $313.24 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $294.38 | 2022-2025 | Oxervate |
| Oyster Point Pharma, INC. | $258.83 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Astellas Pharma US INC | $172.41 | 2024-2025 | Izervay |
| Harrow Eye, LLC | $159.76 | 2024-2025 | Vevye |
| Abbvie INC. | $149.63 | 2023-2025 | |
| Ocular Therapeutix, INC. | $123.20 | 2024 | Dextenza |
| Amgen INC. | $110.07 | 2024-2025 | Tepezza |
| Abb Con-Cise Optical Group LLC | $107.44 | 2025 | Contact Lens, Spectacle Lenses |
| Novartis Pharmaceuticals Corporation | $75.21 | 2023 | |
| Horizon Therapeutics Plc | $72.91 | 2022-2023 | Tepezza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $38.86 | 2022-2024 | |
| Thea Pharma INC. | $35.01 | 2022 | |
| Rxsight INC | $30.95 | 2022 | |
| Apellis Pharmaceuticals, INC. | $24.19 | 2023 | Syfovre |
| Eyevance Pharmaceuticals LLC | $21.80 | 2022 | |
| Genentech USA, INC. | $21.32 | 2024 | Vabysmo |
| Johnson & Johnson Vision Care, INC. | $18.95 | 2025 | |
| Notal Vision, INC. | $18.83 | 2025 | Foresee Home |
| Optos, INC. | $17.40 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Coopervision INC. | $16.72 | 2023 | Onefit Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Van Meter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.